NCT05262530 is a Phase 1, PHASE2 clinical trial of BNT142 in Solid Tumor, sponsored by BioNTech SE.

Who is sponsoring NCT05262530?

NCT05262530 is sponsored by BioNTech SE.

What drugs are being tested in NCT05262530?

Interventions in NCT05262530: BNT142.

What condition does NCT05262530 study?

NCT05262530 studies Solid Tumor.

Is NCT05262530 still recruiting?

NCT05262530 is currently terminated. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT05262530

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Terminated Phase 1, PHASE2 Last updated 8 April 2026

What this trial tests

Phase 1, PHASE2 trial testing BNT142 in Solid Tumor in 73 participants. Terminated before completion.

Timeline

22 March 2022

Primary endpoint
22 December 2025

22 December 2025

Quick facts

Lead sponsor	BioNTech SE
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	73
Start date	22 March 2022
Primary completion	22 December 2025
Estimated completion	22 December 2025
Sites	18 locations across Singapore, United Kingdom, United States, Spain

Drugs / interventions tested

BNT142 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

BioNTech SE — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.
Shi Y, Shi M, Wang Y, You J. · · 2024 · cited 67× · PMID 39543114 · DOI 10.1038/s41392-024-02002-z
Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape.
Li X, Qi J, Wang J, Hu W, et al · · 2024 · cited 47× · PMID 38169577 · DOI 10.7150/thno.84291
Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery <i>in vivo</i>.
Zhang T, Yin H, Li Y, Yang H, et al · · 2024 · cited 42× · PMID 38770138 · DOI 10.1016/j.isci.2024.109804
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation.
Yu M, Yang W, Yue W, Chen Y. · · 2022 · cited 35× · PMID 36257824 · DOI 10.1002/advs.202204335
mRNA-Based Therapeutics in Cancer Treatment.
Sun H, Zhang Y, Wang G, Yang W, et al · · 2023 · cited 33× · PMID 36839944 · DOI 10.3390/pharmaceutics15020622
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6.
Stadler CR, Ellinghaus U, Fischer L, Bähr-Mahmud H, et al · · 2024 · cited 32× · PMID 38776391 · DOI 10.1126/scitranslmed.adl2720
Clinical development of therapeutic mRNA applications.
Żak MM, Zangi L. · · 2025 · cited 28× · PMID 40143545 · DOI 10.1016/j.ymthe.2025.03.034
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.
Qin X, Ning W, Liu H, Liu X, et al · · 2024 · cited 28× · PMID 38828136 · DOI 10.1016/j.apsb.2024.03.027

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other BioNTech SE trials

Trials by the same sponsor.

NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
NCT07069309 — A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 1 · Phase 3 · active not recruiting
NCT06821061 — A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People · Phase 1, PHASE2 · completed
NCT05630352 — A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05262530 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioNTech SE
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05262530.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing